Edgewise Therapeutics, Inc. — Director's Dealing 2021

Mar 26, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Edgewise Therapeutics, Inc. (EWTX)
CIK: 0001710072
Period of Report: 2021-03-25

Reporting Person: ROOT JONATHAN D (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B-1 Preferred Stock	$0.00		Common Stock (1651607)		Indirect
Series B-2 Preferred Stock	$0.00		Common Stock (1366707)		Indirect
Series C Preferred Stock	$0.00		Common Stock (455229)		Indirect

Footnotes

F1: Immediately prior to the completion of the Issuer's initial public offering of Common Stock, each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock and Series C Preferred Stock shall be exchanged at a 1:1 ratio for shares of Common Stock.

F2: These securities are held of record by U.S. Venture Partners XI,L.P. ("USVP XI"). Presidio Management Group XI, L.L.C. ("PMG XI"), the general partner of USVP XI, has sole voting and dispositive power with respect to the shares held by USVP XI. The Reporting Person is a managing member of PMG XI with additional rights with respect to the issuer's securities, and may be deemed to have sole voting an dispositive power with respect to such shares. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.